AbbVie Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ABBV34.SA | BMY | LLY.F | PFE | 0QYQ.IL | BIIB | |
|---|---|---|---|---|---|---|
| Market cap | 2.84T | 131.21B | 1.14T | 175.50B | 215.56B | 37.61B |
| P/E (TTM) | 54.6 | 14.2 | 48.1 | 44.0 | 39.8 | 110.2 |
| Forward P/E | — | 9.6 | 60.1 | 10.6 | — | 15.6 |
| Price/book | -6.0 | 5.6 | 31.7 | 2.1 | 10.2 | 2.0 |
| Dividend yield | 1.54% | 3.93% | 0.49% | 5.59% | 3.81% | — |
| 1-year change | +34.19% | +37.66% | +57.42% | +23.90% | +38.91% | +62.35% |
| Today | +2.92% | +4.02% | +0.73% | +2.63% | +0.58% | +2.22% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All ABBV34.SA news ›AbbVie Inc Stock (ABBV) Closed Up by 3.09% on Nov 4: Key Drivers Unveiled
TradingKey AbbVie Inc Stock (ABBV) Closed Up by 3.09% on Nov 4: Key Drivers Unveiled What is driving AbbVie Inc (ABBV)’s stock price up today? AbbVie experienced strong upward momentum accompanied by heightened intraday volat
Latham & Watkins Advises AbbVie on Global License Agreement With Nxera Pharma
Latham & Watkins LLP Nxera Pharma Co., Ltd. (TSE: 4565) today announces that its subsidiary, Nxera Pharma UK Ltd, has entered into an exclusive global license agreement with AbbVie Inc. for Nxera’s EP4 agonist program, inc
AbbVie licenses Nxera's oral EP4 receptor agonist for IBD with up to USD 1.47b
AllSci AbbVie (NYSE: ABBV) is tapping up Japan-based Nxera Pharma Co., Ltd. (Tokyo Stock Exchange: 4565) for an exclusive global license to develop and commercialize NXE0033744, a Phase I-stage investigational oral EP4 re
AbbVie (NYSE:ABBV) Price Target Raised to $338.00
Posted by Sarita Garza on Nov 5th, 2026 AbbVie (NYSE:ABBV – Free Report) had its price objective increased by Canaccord Genuity Group from $290.00 to $338.00 in a research report report published on Monday morning, Marketbeat reports. The…
AbbVie expands Oxford R&D as part of more than £120m investment in UK life sciences
PMLiVE AbbVie expands Oxford R&D as part of more than £120m investment in UK life sciences AbbVie has announced the expansion of its UK R&D facility, AbbVie Oxford. The new 12,000-square-foot site will expand AbbVie
AbbVie, Nxera ink licensing deal worth up to $1.5B for bowel disease therapy
AbbVie (ABBV) agrees to buy exclusive global rights to develop and commercialize a bowel disease drug from Nxera Pharma in a deal worth up to $1.5B. Read more here. Nxera Pharma (SOLTF) on Wednesday announced a licensing agreement worth up…
AbbVie bets up to $1.47B for Nxera’s discarded IBD program
AbbVie is doling out $100 million in cash to gain exclusive licensing rights to Nxera Pharma’s EP4 receptor agonist program in inflammatory bowel disease. Under the terms of the deal, Nxera could collect up to $1.37 billion more in…
AbbVie expands Oxford R&D facility as part of £120 million-plus investment
Nov 4 (Reuters) – AbbVie has expanded its UK research and development facility in Oxford as part of a more than £120 million ($161 million) investment, the US drugmaker said on Wednesday. The investment comes a few months after the US…
More from 1 other outlet
AbbVie (ABBV) Receives a Rating Update from a Top Analyst
Leerink Partners analyst David Risinger reiterated a Buy rating on AbbVie today and set a price target of $325.00. According to TipRanks, Risinger is a top 100 analyst with an average return of 32.8% and a 65.44% success rate. Risinger…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com33
- theglobeandmail.com20
- fool.com19
- seekingalpha.com16
- themarketsdaily.com13
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.